I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Ie-Ming Shih, M.D., Ph.D.
Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics
Professor of Gynecology and Obstetrics
Languages: English, Chinese, Taiwanese
Expertise: Gynecologic/Obstetric Pathology, Pathology
Research Interests: Cancer Pathogenesis; Cancer Diagnostics; Molecular Cancer Therapy
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Johns Hopkins Hospital (Main Entrance)
Appointment Phone: 410-502-7774
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287 map
Dr. Ie-Ming Shih is the Richard TeLinde Distinguished Professor of Gynecologic Pathology at the Johns Hopkins University School of Medicine. Dr. Shih directs the Richard W. TeLinde Gynecologic Pathology Laboratory in the Department of Gynecology and Obstetrics and co-directs the Breast and Ovarian Cancer Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions.
Dr. Shih received his M.D. from Taipei Medical University and earned his Ph.D. in pathology from the University of Pennsylvania. Dr. Shih went on to do a clinical fellowship in gynecologic pathology and a research fellowship in cancer genetics at Johns Hopkins before joining the faculty in 2001.
Dr. Shih has published extensively on basic and translational research related to gynecologic pathology and oncology, with more than 300 original publications and book chapters. His research focuses on molecular and translational studies in various gynecological disorders, especially ovarian cancer and endometriosis. His research team helps elucidate the genomic landscape in ovarian clear cell carcinoma, ovarian low-grade serous carcinoma and uterine serous carcinoma as well as endometriosis. Dr. Shih’s research team has contributed to the discovery and functional characterization of cancer associated genes and the pathway they controlled including ARID1A, Rsf-1, Syk, NAC1 and Notch3 in ovarian cancer. Dr. Shih in collaboration with Dr. Kurman has proposed the dualistic model (Type I and Type II) in ovarian cancer pathogenesis, which has become a well-accepted model in studying ovarian cancer. Based on molecular genetic analysis in ovarian cancer, Dr. Shih's research team is exploring new molecular targets and pathways for experimental therapeutics and are initiating new clinical trials based on their new findings. Currently, Dr. Shih's research has been supported by NIH/NCI, Ovarian Cancer Research Foundation Alliance, Gray Foundation, and various sources. He sits in several advisory boards such as NCI Ovarian Task Force of Gynecologic Cancer Steering Committee (for clinical trials on gynecologic cancer), Ovarian Cancer Research Foundation, and International Society of Gynecologic Pathology/World Health Organization (WHO) Nomenclature Committee for Gynecologic Neoplasms in addition to SPORE external advisory board and various study sections of NCI, DoD among several others. Besides his clinical, research and teaching obligations, Dr. Shih is a passionate photographer.
- Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics
- Director of TeLinde Gynecologic Pathology Laboratory
- Co-Director, Breast and Ovarian Cancer Program, Sidney Kimmel Comprehensive Cancer Center
- Professor of Gynecology and Obstetrics
- Professor of Oncology
- Professor of Pathology
Departments / Divisions
- MD, Taipei Medical University (1988)
- Taipei Institute of Pathology / Anatomic Pathology (1989)
- Johns Hopkins University School of Medicine / Anatomic Pathology (1997)
- The Wistar Institute / Pathology (1994)
- Johns Hopkins University School of Medicine / Anatomic Pathology (2000)
- American Board of Pathology / Anatomic Pathology (1997)
Research & Publications
Dr. Shih's research team pursues out-of-the-box approaches at the very edges of knowledge to:
- elucidate the molecular/cellular/physiological landscapes of ovarian and uterine cancers,
- understand the earliest events in their development and mechanisms of tumor evolution/dormancy and drug resistance,
- deliver promises for better prevention, detection and treatment to women who have diseases or are at an increased risk to have these cancers.,
- study the etiology of endometriosis and how to design a better classification system and interventions to treat endometriosis.
Please see www.gynecologycancer.org for details about Dr. Shih's research.
Lab Website: Gynecologic Pathology Laboratory
Selected PublicationsView all on Pubmed
Yu Y, Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM. Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell, 28:82-96, 2015
Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances hTERT transcription and maintains telomere length in cancer cells. J Biol Chem, 291:9690-9699, 2016. PMID: 26953344
Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM. ARID1A deletion in collaboration with PTEN deletion leads to ovarian tumorigenesis in mouse. J Natl Can Inst. 2014, Jun 4;106(7). pii: dju146. doi: 10.1093/jnci/dju146. Print 2014 Jul. PMCID: PMC4056776
Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Revisited, Revised and Expanded. Am J Pathol, 186:733-747, 2016. PMID: 27012190
Kuhn E, Wu RC, Wu G, Guan B, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Levine DA, Kurman RJ, Wang TL, Shih IM. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53. J Natl Can Inst, 104:1503-1513, 2012. PMCID: PMC3692380
Activities & Honors
- Molecular diagnostics for malignant effusion, NCI/NIH , 2004 - 2012
- The Roles of HBXAP Gene in Ovarian Cancer, NCI/NIH , 2008 - 2013
- Pathogenesis of ovarian serous borderline tumors, NCI/NIH , 2007 - 2011
- Consortium Planning Award , Department of Defense, Ovarian Cancer Research Program , 2009 - 2010
- Nanobiosensing Method for Point Mutation Detection of Cancer, NCI/NIH , 2008 - 2010
- Notch3 Signaling Pathway in the Ovarian Carcinoma, American Cancer Society , 2008 - 2012
- American Association for Cancer Research
- United States and Canadian Association of Pathologists
- NCI/NIH, Member of Cancer Molecular Pathobiology Study Section (CAMP), 2006 - 2011
- NCI/NIH, L (12)B Cancer Diagnostic & Treatment Study Section, 2005 - 2007
Member of Onc
- NCI/NIH, IMAT (R21/R33) New innovative technology in cancer, 2002
Ad Hoc member
- NCI/NIH, Cancer Biomarkers Research Group, 2008
Early Detection Network (EDRN)
- Ovarian cancer research program, US DoD, 2005 - 2009